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Abstract
Curcumin, a polyphenol from turmeric (Curcuma longa),
reduces inflammation, atherosclerosis, and obesity in several
animal studies. In Ldlr2/2 mice fed a high-fat diet (HFD), curcu-
min reduces plasma lipid levels, therefore contributing to a
lower accumulation of lipids and to reduced expression of fatty
acid transport proteins (CD36/FAT, FABP4/aP2) in peritoneal
macrophages. In this study, we analyzed the molecular mecha-
nisms by which curcumin (500, 1000, 1500 mg/kg diet, for 4
months) may influence plasma and tissue lipid levels in Ldlr2/2
mice fed an HFD. In liver, HFD significantly suppressed cAMP
levels, and curcumin restored almost normal levels. Similar
trends were observed in adipose tissues, but not in brain, skele-
tal muscle, spleen, and kidney. Treatment with curcumin
increased phosphorylation of CREB in liver, what may play a
role in regulatory effects of curcumin in lipid homeostasis. In
cell lines, curcumin increased the level of cAMP, activated the
transcription factor CREB and the human CD36 promoter via a
sequence containing a consensus CREB response element.
Regulatory effects of HFD and Cur on gene expression were
observed in liver, less in skeletal muscle and not in brain. Since
the cAMP/protein kinase A (PKA)/CREB pathway plays an impor-
tant role in lipid homeostasis, energy expenditure, and thermo-
genesis by increasing lipolysis and fatty acid b-oxidation, an
increase in cAMP levels induced by curcumin may contribute
to its hypolipidemic and anti-atherosclerotic effects. VC 2016
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1. Introduction
Curcumin (Cur) is a polyphenol derived from the rhizome of tur-
meric (Curcuma longa), which is traditionally used as spice and
for prevention and therapy of many diseases in Asian countries.
Cur affects a number of cellular functions in cell culture as well
as in animal models and human clinical trials (reviewed in refs.
1–5). In animal studies, Cur lowers the plasma lipid levels and
reduces obesity and atherosclerosis [6–10]. Thus, some of the
lipid-lowering effects of Cur in plasma might be responsible for
its beneficial effects against several conditions in which hyper-
lipidemia plays important roles, such as inflammation, diabetes,
obesity, and atherosclerosis.
Abbreviations: cAMP, cyclic adenosine monophosphate; Cur, curcumin;
HFD, high-fat diet; Ldlr, low-density lipoprotein receptor; LDL, low-density
lipoprotein
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Several mechanisms have been proposed to explain the
hypolipidemic effects of Cur (reviewed in ref. 11); however, the
molecular mechanisms are not yet completely clear and, as
outlined below, it may involve several regulatory pathways.
We and others have reported that Cur activates AMP-activated
kinase (AMPK) in adipocytes and myotubes, the master switch
in energy metabolism and fatty acid oxidation [6,12]. Hepatic
steatosis is also attenuated by Cur through activation of AMPK
[10,13]. In cultured monocytes/macrophages, Cur enhances the
activity of the forkhead box O3a (FOXO3a) transcription factor
by increasing its phosphorylation and nuclear localization,
leading to induction of the expression of FOXO3a-target genes
(e.g., sterol carrier protein, 3-hydroxy-3-methylglutaryl-CoA
synthase, CD36, FABP4/aP2, MnSOD, catalase, eNOS) relevant
for lipid accumulation and resistance to oxidative and lipid-
mediated stress [8]. Interestingly, Cur increases lipid levels in
monocytes/macrophages in cultured cells, but it decreases lipid
levels in peritoneal macrophages of Ldlr2/2 mice supple-
mented with Cur, suggesting that in vivo uptake and metabo-
lism of Cur is different and may play a role in lipid homeosta-
sis [8,14,15]. Accordingly, the fatty acid transport proteins,
CD36/FAT and fatty acid binding protein 4 (FABP4/aP2), are
induced by Cur in cultured THP-1 monocytes/macrophages,
whereas in peritoneal macrophages of Ldlr2/2 mice, their
expression is suppressed after Cur supplementation [8]. Based
on these results, we have proposed a model in which the hypo-
lipidemic effect of Cur leads to a lower exposure of peritoneal
macrophages to plasma lipids, which in turn downregulates
CD36 and aP2 with consequent lower lipid accumulation in
these cells [8].
The plasma lipid level is predominately influenced by the
interplay of liver, skeletal muscle, and adipose tissues. In these
tissues, the cAMP/PKA/CREB signaling pathway plays impor-
tant roles in lipid homeostasis by increasing PKA-mediated
lipolysis and fatty acid oxidation [16,17]. In the liver, cAMP/
PKA regulates lipid homeostasis by modulating energy expend-
iture and thermogenesis, by decreasing liver VLDL secretion
and increasing lipolysis and fatty acid oxidation [18–21]. In
skeletal/cardiac muscle, cAMP stimulates CD36-mediated lipid
uptake, b-oxidation, and mitochondrial biogenesis [22,23], and
protects against muscle atrophy by inhibiting the ubiquitin–
proteasome system [24]. In skeletal muscle, lipid uptake is
stimulated by CD36 membrane exposition and controlled by
FOXO1 by yet unclear molecular mechanisms [25–27]. In adi-
pocytes as well as in atherosclerotic lesions, increased cAMP
decreases lipid content [18]. Thus, as described recently for
the polyphenol resveratrol [28], upregulation of tissue cAMP
levels by Cur could be at the basis of its hypolipidemic and
anti-atherosclerotic effects and similar to other nutritional
supplements such as forskolin or caffeine, it may also explain
its effect on weight loss [6,21,29].
In this study, using cell culture and in vivo animal models,
we have investigated whether the induction of cAMP levels in
different tissues and subsequent stimulation of lipid transport-
ers and catabolic genes by Cur could be at the basis of its
hypolipidemic effects. As an in vivo experimental model, we
used the Ldlr2/2 mouse which is a good animal model of high-
fat-induced accelerated hyperlipidemia and atherosclerosis,
since when fed a high-fat Western style diet, these mice show
a high concentration of circulating cholesterol and develop
lipid-mediated stress (accumulation of lipids, inflammation,
increased oxidative stress) at 8 weeks [30]. Our results suggest
that a regulatory role of Cur on cAMP-mediated signaling and
gene expression may contribute to its effects on prevention of
atherosclerosis and inflammation.
2. Materials and Methods
2.1. Materials
Curcumin (Cur), curcuminglucuronide (CurG)), curcuminsul-
phate (CurS), demethoxycurcumin (DCur), bisdemethoxycurcu-
min (BDCur) (Toronto Research Chemicals, Inc., Canada), and
tetrahydrocurcumin (THC) (kindly provided by V. Badamov,
Sbinsa Corporation, Piscataway, NJ) were dissolved in ethanol
as 20 mM stock solution. The adenylate cyclase activators, for-
skolin (20 mM), and 20-50-dideoxyadenosine (50 mM), or the
phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine
(IBMX) (500 mM) (Sigma-Aldrich, St Louis, MI) were dissolved
in ethanol and diluted with ethanol upon usage.
2.2. Cell Culture and Treatments
The human acute monocytic leukemia cell line THP-1 (TIB-202,
American Type Culture Collection (ATCC)) was cultured in RPMI
1640 medium, 10% fetal calf serum, 2 mmol/L L-glutamine, 1.0
mmol/L sodium pyruvate, 4.5 g/L glucose containing 100 lg/mL
streptomycin and 100 U penicillin. Human embryonic kidney
293 (HEK293) cells (CRL-1573, ATCC) were grown in Dulbecco’s
modified Eagle’s medium, 10% fetal calf serum, and 2 mmol/L
L-glutamine containing 100 lg/mL streptomycin and 100 U/mL
penicillin. THP-1 monocytes (1 3 106/6 well plate) and HEK293
cells (0.3 3 106/6 well plate) were plated 24 h before treatment
with compounds.
2.3. Animal Feeding Protocol
Ldlr2/2 C57BL/6 male mice (Jackson Laboratory, Bar Harbor,
ME) were individually housed at the Jean Mayer Human Nutri-
tion Research Center on Aging (HNRCA) Comparative Biology
Unit at Tufts University. The mice were kept on a 12 h light/
dark cycle and had free access to food and water. After accli-
mation for 1 week, 8-week-old mice were randomly assigned
to five groups of 24 mice each. One group of mice was fed an
AIN-93M diet (Harlan Teklad, TF.08485) for 16 weeks and
served as “low-fat diet (LFD) negative controls.” The other 4
groups of mice were fed a Western style high-fat/cholesterol
AIN-93M diet (HFD) (Harlan Teklad TD.09346) formulated to
contain 0.157% cholesterol and 21% fat by weight for
4 months. AIN-93 mineral and vitamin mixes were used in the
formulation of diets. From the HFD-fed mice, one group of
mice was designated as positive HFD control, and the diets of
the other three groups were either supplemented with a low
(500 mg/kg), medium (1000 mg/kg), and high (1500 mg/kg)
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dose of Cur for 16 weeks. This study was approved by the
HNRCA Institutional Animal Care and Use Committee (IACUC)
at Tufts University (protocol MM-45).
2.4. Sample Preparation from Animal Study
At the end of the study (after 16 weeks), the mice were sacri-
ficed by asphyxiation with CO2 and secondary euthanasia by
cervical dislocation, what is consistent with the recommenda-
tions of the American Veterinary Medical Association. Mouse
body weight, blood lipids and liver weight, histology and analy-
sis of total lipids, cholesterol, triglycerides (TG), high-density
lipoprotein (HDL), low-density lipoprotein (LDL), and glycogen
have been previously reported [10]. Samples of liver, kidney,
brain, spleen, skeletal muscle, and adipose tissue (visceral,
inguinal subcutaneous, interscapular subcutaneous) were fro-
zen in liquid nitrogen and stored at 2808C for later prepara-
tion of extracts for Western blot analysis and cAMP measure-
ments. Moreover, samples of these tissues were collected and
stored in RNAlater solution (Qiagen) at 2808C for extraction of
total RNA.
2.5. Quantitative RT-PCR
Tissues were homogenized with a polytron and total RNA was
isolated using RNeasy Midi kit (Qiagen, Valencia, CA). cDNA
was synthesized by TaqMan Reverse Transcription Reagents
(Applied Biosystems, Foster City, CA). Gene expression of
CD36, UCP1, UCP2, FABP4/aP2, and Sestrin 2 was measured
by quantitative RT-PCR using primers and conditions of the
TaqMan two-step PCR (Applied Biosystems, Foster City, CA).
GAPDH was used as the endogenous control. The reactions
were run in triplicate, and the data were analyzed using the
DDCt method [31].
2.6. Preparation of Tissue Extracts and
cAMP Measurements
Frozen tissues samples (approx 100 mg) were homogenized on
ice in 500 lL 23 Lysis buffer (diluted from 103 Cell Lysis
Buffer (Cell Signaling Technology, Beverly, MA)) containing
protease inhibitors (1 tablet of protease inhibitor TABS
(Roche)/10 mL, 0.5 mM IBMX (Sigma-Aldrich, St Louis, MI),
and 100 lM Ro20-1724 (Sigma-Aldrich)). Extracts were centri-
fuged 14,000g for 15 min at 48C to eliminate debris or large
fragments of DNA, etc., and the protein concentration meas-
ured with BCA kit (Thermo Scientific, Rockford, IL), aliquots of
equal protein concentration prepared, and stored at 2708C.
For measuring cAMP levels, these aliquots were heated to
708C for 10 min and centrifuged at 14,000g at 48C for 10 min.
Tissue cAMP levels in homogenized tissues (heart, liver, adi-
pose tissues, intestine, skeletal muscle, brain) were measured
relative to cAMP standard using a Meso Scale cAMP assay sys-
tem and Sector Imager 2400 reader (Meso Scale Discovery,
Gaithersburg, MD). The same extracts were used for Western
blotting.
2.7. cAMP Measurements in Cultured Cells
Cellular cAMP levels in response to Cur or THC were meas-
ured with the cAMP-Glo assay according to the manufacturer’s
protocol (Promega, Madison, WI) using a GloMaxVR -Multi
Microplate Multimode Reader (Promega, Madison, WI).
2.8. Real-Time cAMP Measurements in Cultured Cells
Real-time cellular cAMP levels in response to Cur and Cur
metabolites in HEK293 cells were measured using the cAMP
Glo sensor assay system (Promega). For long-term treatments
(24 h), cells were transfected with the cAMP reporter vector
pGloSensorTM-22F (Promega, Madison, WI) for 3 h, then
treated with Cur analogs at the indicated concentrations for
24 h, upon which the medium was changed to GloSensor rea-
gent, pre-equilibrated at room temperature for 1 h, and the
cAMP levels measured at different time points thereafter
according to the supplier’s protocol using a GloMaxVR -Multi
Microplate Multimode Reader (Promega). For short-term
measurements (0–6 h), the cells were grown for 24 h after
transfection and the treatment with Cur analogs occurred after
changing medium to GloSensor reagent and pre-equilibrating
at room temperature for 1 h.
2.9. Plasmids, Transfection, and Luciferase
Reporter Assays
The human CD36 promoter firefly luciferase reporter plasmids
used were pCDextpro containing 4557 bp of the human CD36
promoter [8], and pCDbasic [32,33] containing only a short pro-
moter. CD36 promoter deletions constructs were generated
from pCDextpro [8] deleting parts by restriction digestion, filling
the ends with Klenow polymerase fragment when necessary and
religation, resulting in plasmids pCDDEcoRI, pCDDMluI/PvuII,
pCDDMluI/StuI, pCDDStuI, and pCDDMluI/MluNI. THP-1 mono-
cytes or HEK293 cells were transfected with Fugene (Promega)
for 3 h with the indicated reporter plasmids and then treated
with 0.1% ethanol (solvent control) or curcumin for an additional
21 h. Extracts were prepared, and promoter activities were
measured using the Dual-Luciferase assay kit (Promega, Madi-
son, WI) with a GLOmax luminometer (Promega). The promoter-
Firefly luciferase activities were normalized to the thymidine
kinase promoter-Renilla luciferase activities (pRL-TK), and the
activities of the control transfections were set to 100%.
2.10. Measurement of CREB, NRF2,
and PPARc Activity
The activity of the transcription factor CREB was measured by
transfecting luciferase reporter vectors for CREB (pCREB-RE-
luc, Clontech, Mountain View, CA), NRF2 (pARE-RE-luc [34]), or
PPARc (pDR1-Luc [35]). These plasmids were transfected into
HEK293 or THP-1 cells together with the Renilla internal control
plasmid pRL-TK (Promega) for 3 h using Fugene (Promega) as
transfection reagent. Extracts were prepared, and promoter
activities were measured as described above.
2.11. Western Blotting
Cells (2 3 106 cells in 10 mL media per dish) were harvested
and Western blots prepared as previously described [8]. For
tissues, extracts were prepared as described above for cAMP
measurements. The level of CREB phosphorylation was deter-
mined using primary anti-phospho-CREB (Ser473), primary
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anti-CREB antibody (all from Cell Signaling Technology), and
horseradish peroxidase coupled donkey antirabbit IgG second-
ary antibody (Amersham Biosciences, Piscataway, NJ). CD36
was measured using monoclonal rabbit antimouse CD36 anti-
body, Western blots for UCP1 and UCP2 (Supporting Informa-
tion, Fig. 1) were measured using polyclonal rabbit antimouse
UCP1 and antihuman UCP2 antibodies (all from Abcam, Cam-
bridge, MA). Monoclonal mouse antihuman b-actin (1:10,000
diluted) (Sigma-Aldrich) was used as primary control antibody
for liver and cell culture extracts, and mouse monoclonal anti-
GAPDH (Abcam) for skeletal muscle extracts. Antimouse and
antirabbit secondary antibodies coupled to horseradish peroxi-
dase (Santa Cruz, Santa Cruz, CA) were used for detection. Pro-
teins were visualized with an enzyme-linked chemiluminescence
detection kit (Immun-StarTM HRP) according to the manufac-
turer’s instructions (Biorad, Hercules, CA). Chemiluminescence
was monitored by exposure to film (Kodak BioMax), and the sig-
nals were analyzed using a FluorchemTM 8900 workstation and
the AlphaEaseFC software (AlphaInotech, San Leandro, CA).
2.12. Statistical Analysis
All values are expressed as the mean6 standard errors (SEM)
as inscribed in the figure legends. Student’s t-test was used to
analyze the significant differences between two treatments.
One-way ANOVA followed by Tukey’s post hoc test was used
for multiple comparisons. P<0.05 is considered to indicate a
significant difference. All data were analyzed using XLstat.
3. RESULTS
3.1. Curcumin Restores HFD-Reduced Levels of cAMP
and Increases CREB Phosphorylation in the Liver
To investigate whether the previously observed regulatory
effects of Cur on hypolipidemia [8,14,15] possibly occur via
activation of the cAMP/PKA/CREB pathway that plays an
important role in lipid homeostasis, energy expenditure, and
thermogenesis, we measured the effect of Cur on cAMP levels
in the liver and several other tissues of Ldlr2/2 mice treated
with LFD, or an HFD and an HFD supplemented with three
doses of Cur (500, 1,000, and 1,500 mg/kg) for 16 weeks. In
the liver, an HFD significantly decreased liver cAMP levels
compared to LFD, and Cur increased it (Fig. 1A). A similar but
not significant effect of HFD and Cur was observed in adipose
tissues [36] collected from inguinal subcutaneous and visceral
fat depots (Fig. 1B), but less in interscapular subcutaneous fat
depots (Fig. 1B), in spleen, kidney, skeletal muscle, and brain
tissues (Fig. 1C). In liver, where the Cur effect on cAMP was
strongest, Cur also increased the p-CREB/CREB ratio, suggest-
ing that it may contribute to the regulatory effects of Cur on
gene expression mainly observed in this tissue (Fig. 1D) [37].
3.2. A High-Fat Diet and Curcumin Increase CD36
Gene Expression in Liver of Ldlr2/2 Mice
Ldlr-/- mice lack the LDL receptor, the major route for lipid
uptake by the liver, suggesting that HFD-induced steatohepato-
sis may result from the HFD increased expression of another
receptor such as the CD36/FAT scavenger receptor/fatty acids
transporter, which at least in humans is upregulated during
nonalcoholic fatty liver disease (NAFLD) [38]. Based on this
assumption, the level of CD36 mRNA and protein was meas-
ured by quantitative PCR and Western blotting in the liver
samples of the above mice. HFD increased liver CD36 expres-
sion at mRNA and protein levels (Fig. 2A), the stronger induc-
tion of CD36 at the mRNA level when compared to the protein
level may suggest some post-transcriptional regulation such as
alternative splicing, protein turnover [33,39], or regulatory
effects of microRNAs that are regulated by curcumin [40]. Sup-
plementing the HFD with 500 mg/kg Cur slightly increased the
mRNA expression of CD36, whereas higher levels of Cur
(1,000 and 1,500 mg/kg diet) slightly reduced it (Fig. 2A).
CD36 expression at the protein level was slightly increased by
Cur (500 and 1,000 mg/kg diet) in liver, and again decreased
at the highest Cur concentration (1,500 mg/kg diet) (Fig. 2B).
Much weaker regulatory effects were observed in skeletal
muscle, where HFD rather decreased CD36 expression, but
Cur at low concentration (500 mg/kg diet) still increased it,
whereas Cur at higher concentrations (1,000 and 1,500 mg/kg
diet) again decreased it (Fig. 2C). Similar patterns of gene
expression was measured in liver for the fatty acid binding
protein 4 (FABP4/aP2), uncoupling proteins 1 and 2 (UCP1/2),
and sestrin 2 (SESN2), but they were weaker and mostly not
significant (Supporting Information, Fig. 1). Whereas in other
tissues such as skeletal muscle and brain, no regulatory
effects on these genes were observed (Supporting Informa-
tion, Fig. 2). Thus, when comparing the cAMP data (Fig. 1)
with the CD36 gene expression data (Fig. 2), it appears that
in HFD-treated mice Cur can increase cAMP levels and CD36
expression, but that in liver the induction of CD36 expression
by Cur is lower since HFD already robustly upregulates CD36
expression by alternative pathways such as PPARc activation
[15,41,42] or by Ca21 signaling in response to fatty acids
sensing [43].
3.3. Curcumin Increases cAMP and Activates
CREB in Cultured Cells
CD36 expression is regulated by several transcription factors,
of which PPARc [44], SREBPs 1c and 2 [45], NRF2 [46–48], and
CREB [49] have been shown to be responsive to Cur supple-
mentation and elevated lipids (reviewed in ref. 11). To assess
which transcription factor(s) may be involved in the effects
observed with HFD and Cur treatments and whether a similar
regulation also occur in human cells, reporter vectors contain-
ing response elements for PPARc, NRF2, and CREB in front of
the luciferase gene were transfected into HEK293 cells,
treated with Cur (5 and 10 lM) for 24 h, and the transcrip-
tional activity measured. These cells were used as a model
system since they are of epithelial origin, are efficiently trans-
fected and are able to take up Cur and metabolize it [50]. Cur
slightly activated PPARc and NRF2, but the effects were
strongest for CREB (Fig. 3A), which might be activated by
cAMP/PKA [51,52]). To investigate whether CREB could be
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involved in the upregulation of the human CD36 promoter in
response to Cur, cells were treated with the bona fide adenyl-
ate cyclase (AC) stimulator forskolin (10 lM) which activates
CREB by increasing the level of cAMP. Indeed, the CD36 pro-
moter construct was stimulated by forskolin (Fig. 3B) suggest-
ing that CREB can be involved in the upregulation of CD36
expression induced by Cur.
Cur is rapidly metabolized in cultured cells and some metabo-
lites may have a higher activity [50]. To evaluate whether metabo-
lites of Cur were responsible for the effects on cAMP and CREB-RE
activity, the major metabolites of Cur, such as tetrahydrocurcumin
(THC), curcuminglucuronide (CurG), curcuminsulphate (CurS),
demethoxycurcumin (DMCur), and bisdemethoxycurcumin
(BDCur) were tested [53]. Interestingly, with the exception of THC,
these metabolites increased CREB-RE activity with similar effi-
ciency as Cur within 24 h (Fig. 3C), suggesting that Cur conversion
to active metabolites may also contribute to its bioactivity. Differen-
ces measured between Cur and THC in activating cAMP and CREB
phosphorylation could be due to their different ability to inhibit
phosphodiesterases (PDE) or to stimulate adenylate cyclases (AC)
activity [54,55], as reported for resveratrol [28]. At the molecular
level, Cur and THC may have different affinity to receptors and
enzymes and/or be converted to different metabolites.
3.4. A Distant Promoter Fragment Containing a
Consensus CREB-Response Element Mediates the
Stimulatory Effects of Cur on CD36 Expression
The mechanisms of CD36 promoter regulation have been
investigated in a number of studies and several regulatory ele-
ments (PPARc, NRF2, HIF1a, SREBP1/2, LXR, PXR, C/EBPa/b)
have been identified in the mouse gene [14,47,56–58]. The
organization of the human CD36 gene is complex [39] and the
location of these regulatory elements in the promoter has not
yet been resolved. To narrow down the regulatory region that
is involved in the regulation of the human CD36 promoter, sev-
eral deletions were introduced and the effect of Cur tested.
Cur induced CD36 promoter activity with the full-length con-
struct (pCDextpro), as well as with the DMluI/MluNI construct
(pCDDM/MI), but not with any of the other constructs, suggest-
ing that the Cur responsive element is within a MluNI/EcoRI
fragment of 480 bp (Fig. 4A). Analysis of the sequence of this
fragment by the TFSEARCH program revealed the presence of
Quantification of cAMP levels in liver and adipose tissues. (A) Livers from Ldlr2/2 mice fed a low- or high-fat diet (LFD or HFD,
respectively) supplemented for 16 weeks with various concentrations of low, medium, and high Cur (500, 1000, and 1500 mg/kg
diet, respectively) were homogenized and cAMP levels measured by Mesoscale cAMP assay (n5 22, 6SEM, *P<0.05, relative to
control fed an LFD set to 100%). (B) Similar, but less pronounced results were obtained with adipose tissues (inguinal subcutane-
ous, visceral and less with interscapular subcutaneous fat) (n5 8, 6SEM), as well as with (C) spleen (n5 8, 6SEM), but less with
skeletal muscle, kidney, and brain (n5 8, 6SEM). (D) Regulation of CREB phosphorylation by HFD and Cur as assessed Western
blots of liver extracts. The level of phospho-CREB was calculated relative to unphosporylated CREB and plotted (n5 12, 6SEM,
*P<0.05, with control (LFD) set to 100%).
FIG 1
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a bona fide consensus binding site for CREB (TGACCTCA) sug-
gesting that Cur may act via this element (Fig. 4B). Interest-
ingly, deletion of the MluI/MluNI fragment (pCDDM/MI) also
released the CD36 promoter from an inhibitory effect of basal
promoter activity, and analysis of the MluI/MluNI fragment
revealed the presence of a bona fide NRF2 response element
(ATGAATCAG) (not shown), which can both stimulate or inhibit
transcriptional activity depending whether positive (NRF2) or
negative (BACH1, MAF) regulatory factors are bound [59].
Close to the CREB binding site, homologies to consensus sites
to other transcription factors were detected (HIF1a, estrogen
receptor (ER), SREBP-1/2 (not shown)), altogether suggesting
that the human promoter contains similar elements as the
mouse promoter but that they are clustered in a more distant
region from the transcriptional start site. The combined action
of these elements may contribute to the regulatory effects
observed of Cur on CD36 expression.
3.5. Real-Time Assay of cAMP Cellular Concentration
after Treatment with Various Curcumin Analogs
Since the above cell culture experiments were all done with an
incubation time of 24 h, differences measured between Cur
and THC on cAMP levels and CREB-RE activity could also be
due to differences in uptake and metabolism within this time-
frame. In fact, we have recently shown that Cur is rapidly
taken up and still detectable 24 h after treatment of THP-1
cells, whereas THC is rapidly metabolized and becomes
undetectable [50]. A similar differential metabolism of Cur and
THC was observed in HEK293 cells (Supporting Information,
Fig. 3).
To assess at which time point, cAMP levels are increased
leading to activation of CREB-RE, a continuous real-time cAMP
assay was used. In this assay, HEK293 cells were transfected
with a cAMP reporter vector pGloSensorTM-22F expressing a
cAMP-luciferase reporter protein, which emits light upon bind-
ing of cAMP and of the substrate Luciferin. Interestingly, upon
short-term treatment with Cur or THC (10 lM) for 0–6 h, THC
had a slightly higher ability to increase cAMP levels in
HEK293 cells, and CurG was even higher whereas BDCur was
lower (Fig. 5A). A robust increase was observed after 2 h with
all compounds tested, and occurred at the concentration of at
least 2.5 lM (Fig. 5B). Interestingly, after 24 h, Cur was more
effective in increasing cAMP levels when compared to THC
(Fig. 5C), which is similar to that of the results obtained for
CREB-RE activity reporter assay (Fig. 3C), suggesting that dif-
ferential uptake and metabolism are at the basis of CD36 pro-
moter activity differences seen with Cur and THC after 24 h.
By comparing the effect of Cur with one of the known controls,
such as the phosphodiesterase (PDE) inhibitor 3-isobutyl-1-
methylxanthine (IBMX) and the adenylate cyclase (AC) activa-
tors (adenosine, forskolin), it is concluded that the effects of
Cur are slower and weaker than adenosine and forskolin but
similar in strength as IBMX (Fig. 5D). An analogous although
weaker regulatory effect of Cur on cAMP levels and CREB-RE
activity was observed in THP-1 monocytes (Supporting Infor-
mation, Fig. 4).
4. Discussion
The liver is an organ with central metabolic functions, includ-
ing lipogenesis, gluconeogenesis, and cholesterol synthesis as
well as the primary site of metabolism for natural dietary com-
ponents [60–62]. Macro and micronutrients such as fatty acids
Regulation of CD36 expression by high-fat diet (HFD) and Cur. Quantitative RT-PCR with cDNA, or western blots of liver
extracts from Ldlr2/2 mice that were fed an LFD, an HFD, and an HFD with a low, medium, and high dose of Cur (500, 1000,
and 1500 mg/kg diet, respectively) for 16 weeks. Expression of liver CD36 mRNA (A) or CD36 protein (B) (expression of mRNA,
n5 4, 6SEM, *P<0.05 relative to LFD, with control (LFD) set to 100%; expression of protein, n512, 6SEM, *P<0.05 relative
to LFD, with control (LFD) set to 100%). Expression of skeletal muscle CD36 protein (C) (n5 8, 6SEM, *P<0.05 relative to LFD,
with control (LFD) set to 100%).
FIG 2
Zingg et al. 47
and Cur influence the metabolism of the liver and its ability to
maintain a normal plasma lipid homeostasis, with consequent
lowering the risk of diseases in which hyperlipidemia and
lipid-mediated stress play important roles, such as inflamma-
tion, steatohepatosis, diabetes, obesity, and atherosclerosis
(reviewed in refs. 9,11,63). In fact, the liver has been reported
to show the strongest transcriptional response upon supple-
mentation by Cur, whereas in other organs such as intestine,
kidney, and spleen, it was weaker or absent [37].
In liver, we found increased CD36 expression in response
to an HFD compared to a LFD, and Cur (500 and 1,000 mg/kg
diet) slightly increased its expression at the protein level.
Although the effects were weak, they might be relevant since
they may occur only in a subset of cells in tissues, such as
endothelial or epithelial cells that are involved in the uptake of
lipids. CD36, also named fatty acids transporter (FAT), is an
important regulator of plasma lipid levels [64], as demon-
strated in several experimental systems in which the level of
expression of CD36 has been modified, for example, by overex-
pressing CD36 or in CD36 knockout mice. These experiments
revealed that the influence of CD36 on plasma lipids depends
on the organ in which CD36 was induced or inhibited [65,66],
and that some organs/tissues are critically dependent on fatty
acids influx by CD36 and for others too much fatty acid influx
may not be desirable. It is important to note that patients with
CD36 deficiency have increased plasma free fatty acid levels
and increased atherosclerotic cardiovascular disease [67],
which suggest that CD36-mediated signaling and lipid removal
from the circulation is a protective mechanism. In contrast,
since heart steady-state energetic metabolism relies mostly on
fatty acids, deficiency of CD36 can lead to hypertrophic cardio-
myopathy and metabolic syndrome [68]. In the liver, CD36
deletion reduces VLDL secretion and increases hepatic steato-
sis [69], suggesting that upregulation of CD36 by Cur may have
protective effects. The here observed increase of CD36 expres-
sion in the liver by HFD and Cur supplementation may particu-
larly be relevant for postprandial uptake of excess fatty acids
mediated by insulin-activated Akt/PPARc/CD36 expression.
In the absence of insulin (e.g., diabetes) or during impaired
insulin signaling (e.g., insulin resistance), a lower activation
of CD36 expression may lead to insufficient removal of
plasma lipids with consequent hyperlipidemia, and it remains
to be investigated whether Cur can also increase CD36 in this
situation [70].
In skeletal muscle, we found that HFD downregulated
CD36 expression, which can be considered as protection of
muscle against accumulation of lipids when lipids are abun-
dant and not needed, for example, in the absence of increased
energy demand induced by exercise, but Cur supplementation
still had an inducing effect on CD36 expression. Again, this
may help in reducing hyperlipidemia since muscle-specific
overexpression of CD36 is associated with lower levels of body
fat, serum free fatty acids, and triacylglycerides and higher
fasting glucose and insulin levels [71].
Several transcription factors have been shown to be
responsive to Cur, and some of them (e.g., PPARc, SREBP-1/2,
NRF2, CREB) have a regulatory role for CD36 expression
(reviewed in ref. 11). Using promoter deletion analysis, the
regulatory effects of Cur were narrowed down to a 480 bp
fragment containing a bona fide CREB response element along
with a number of less conserved elements (HIF1a, NRF2, ER,
SREBP), but the exact Cur-response element(s) within the
Cur activates PPARc, NRF2, and CREB activity in
HEK293 cells. (A) Treatment with Cur (5 and 10 lM)
for 24 h increases PPARc-RE, NRF2-RE, and CREB-RE,
as assessed by transfecting response element lucifer-
ase reporter constructs for these transcription factors
into HEK293 cells. (B) The human CD36 promoter is
controlled by cAMP/CREB. HEK293 cells were trans-
fected with a human CD36 promoter luciferase
reporter constructs and treated with forskolin (10
lM) for 24 h (n 5 4, 6SEM, P<0.05, with untreated
control (c) set to 100%). (C) Differential effects of Cur
metabolites on CREB-RE luciferase activity. HEK293
cells treated with Cur, THC, CurG, DCur, BDCur, or
CurS (all 10 lM) for 24 h and luciferase activity
measured (n5 4, 6SEM, *P<0.05, with untreated
control (c) set to 100%, #P<0.05 relative to Cur).
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human CD36 promoter remain to be determined by a detailed
analysis by mutations, footprinting, and chromatin immuno-
precipitation. Although Cur could increase PPARc activity in
cell culture, activation of the human CD36 promoter by Cur
was independent of PPARc and FOXO3a activation [8,15], indi-
cating involvement of other transcription factors. In cells, Cur
A distant site of the human CD36 promoter containing a CREB consensus site is responsive to Cur. (A) Treatment with Cur (10 lM)
for 24 h increases the full length (pCDextpro) and the DMluI/MluNI CD36 promoter-luciferase reporter construct (pCDDM/MI), but
not any of the other constructs, as assessed by transfection of these constructs into HEK293 cells for 24 h (n5 6, 6SEM, *P<0.05,
with untreated pCDextpro control (c) set to 100%; #P<0.05, compared to transfected plasmid in the absence of Cur). M: MluI, MI:
MluNI, E: EcoRI, P: PvuII, S: StuI. (B) Sequence of the 480 bp Cur-responsive region and identification of a bona fide consensus
regulatory element for CREB.
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stimulated NRF2, Hif1a, and more strongly CREB activity sug-
gesting that these factors may play a role in upregulating
CD36 expression. Moreover, since the response of CD36 to
HFD was different in liver and skeletal muscle, tissue-specific
regulatory mechanisms may be involved, such as HFD-induced
liver CD36 expression as result of PPARc activation [15,41,42].
At the molecular level, we find in liver and less in adipose tis-
sue (visceral, inguinal subcutaneous) and spleen that HFD signif-
icantly decreases and Cur increases tissue cAMP levels, whereas
no significant effect was observed in interscapular subcutaneous
fat, brain, skeletal muscle, and kidney. We recently reported
that Cur is rapidly metabolized in cells [50], which may imply
that the regulatory effects on cAMP may be caused not necessar-
ily by Cur only but also by its metabolites. In fact, in HEK293
cells, the increase of cAMP levels occurred within 4 h at which
the Cur metabolite THC had the strongest effect, whereas after
24 h (the incubation time used for promoter assays), cAMP levels
were highest with Cur rather than Cur metabolites such as THC,
CurG, and BDCur. Therefore, delayed uptake and slower metab-
olism of Cur when compared to THC may be responsible for its
higher stimulatory effect on CD36 expression observed at 24 h.
The level of cAMP influences the activities of protein kinase A
(PKA) and of the transcription factor CREB. These proteins play
important roles in lipid homeostasis, energy expenditure,
and thermogenesis by increasing lipolysis and fatty acid oxida-
tion through stimulation of hormone sensitive lipase (HSL) and
perilipin A [16,17,72]. Thus, according to our data and as out-
lined in the proposed molecular model (Fig. 6), an increase in
cAMP levels induced by Cur could be at the basis of its hypolipi-
demic and antiatherosclerotic effects and similar to other nutri-
tional supplements such as forskolin or caffeine may also
explain its effect on weight loss [20,21,29].
Although it was reported that CREB expression was
decreased in wild-type mice after 2 weeks on a HFD [41], in our
Ldlr2/2 mice treated for 16 weeks, we find slightly elevated CREB
phosphorylation in spite of decreased cAMP. CREB phosphoryla-
tion was stimulated by Cur probably as a result of increasing
cAMP [51,52]). In line with this notion, Cur activated cAMP and
CREB activity in cultured cells. CREB is mainly activated by phos-
phorylation by cAMP-activated protein kinase A (PKA) and subse-
quent nuclear translocation [73], but alternative activation mech-
anisms may also be involved such as the EPAC/PI3K/Akt pathway
[74]. It remains to be resolved whether Cur increases cAMP simi-
lar as resveratrol [28] by inhibiting phosphodiesterases (PDE), or
by stimulating adenylate cyclases (AC) activity [54,55]. CREB is
also activated by nonesterified fatty acids (NEFA) in vascular
smooth muscle cells (VSMC) most likely as a protective response
to NEFA-mediated stress [75]. Since CREB is downregulated in
aortic VSMC in a high-fat-diet-induced model of vascular disease
[73], Cur may normalize CREB and thus be atheroprotective.
Accordingly, increased cAMP decreases lipid content in adipo-
cytes and in atherosclerotic lesions [76].
Regulation of cAMP levels by Cur metabolites. HEK293 cells were transfected with a cAMP reporter vector pGloSensorTM-22F
expressing a cAMP-luciferase reporter protein, which emits light upon binding cAMP and then treated with Cur, THC, CurG, or
BDCur. (A) Time dependence of cAMP accumulation after short term treatment (0–6 h) with Cur or Cur metabolites (all 10 lM).
(B) Concentration dependence of cAMP accumulation after treatment with Cur or Cur metabolites (0.625–20 lM) for 2 h. (C)
Long-term treatment (24 h) with Cur or Cur metabolites (all 10 lM) (n5 2, 6SEM, *P<0.05, relative to untreated control;
#P < 0.05, relative to treatment with Cur). (D) Accumulation of cAMP after treatment for 0–6 h with the adenylate cyclase (AC)
activator forskolin (Forsk, 10 lM) or 20-50-dideoxyadenosine (Ade, 250 lM), or the phosphodiesterase inhibitor IBMX (25 lM).
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At this time, we do not rule out that some of the effects of
Cur on lipid homeostasis may also be mediated by the CREB-
related proteins such as cAMP response element-binding pro-
tein hepatocyte-specific (CREBH) or cAMP response modulator
(CREM), since they also play crucial roles in hepatic lipogene-
sis, fatty acid oxidation, and lipid metabolism by controlling a
number of genes involved in triglyerides metabolism and influ-
ence plasma levels of free fatty acids, triglycerides, and choles-
terol [46,77,78]. CREBH is activated by metabolic stress
induced by saturated fatty acids, insulin signals, or an athero-
genic high-fat diet in the liver [79], and Cur reduced endoplas-
mic reticulum (ER) stress by inhibiting CREBH/CREB3L3 by
stimulating the LKB1/AMPK/SMILE/PGC1a pathway [51]. More-
over, an induction of cAMP and CREBH by Cur may not only
contribute to its hypolipidemic but also its hypoglycemic effects,
e.g., by improving glucose metabolism and insulin resistance
[27,80,81].
A Cur-mediated increase of lipids uptake in liver in the
absence of lipid accumulation may require increased lipid
excretion in bile (e.g., of cholesterol metabolites) (reviewed in
ref. 11) or increased channeling into anabolic pathways (e.g.,
protein and phospholipid synthesis), which is reflected in part
by the observed increase in liver size and preservation of gly-
cogen content [10]. Alternatively, Cur may stimulate energy
dissipation, for example, by direct uncoupling of mitochondrial
oxidative phosphorylation [82], or by upregulation of proteins
involved in catabolic metabolism and metabolic inefficiency
such as UCP1 [83] and AMPK/UCP2 [84–86]. In fact, UCP1 is
regulated by FOXO1 in liver [87] and UCP2 expression is
induced by obesity [88] and Cur [89].
Taken together, our in vivo data suggest that Cur exerts
regulatory effects on cAMP cellular concentrations predomi-
nantly in the liver. At this time, we can only correlate the ele-
vated cAMP levels with the in vivo Cur-induced hypolipidemic
effects, although our in vitro experiments suggest a direct
cause–effect relationship between Cur, cAMP, and the regula-
tion of genes involved in lipid and energy homeostasis such as
CD36, UCP1/2, and aP2. Since the liver centrally participates
in the regulation of plasma lipid, cholesterol, and glucose lev-
els [60–62], it remains to be evaluated to what degree the
observed effects of Cur in other organs are in fact secondary
effects of regulatory events occurring in liver.
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